The Innovation Support Unit’s mission is to foster, boost and disseminate an innovative culture, providing a suitable framework in which to create multi-institutional and inter-disciplinary teams that can come together and collaborate in the joint design of technologies, and so enable them to find solutions to as yet unresolved clinical problems.
The Unit’s objective is to convert ideas into benefits for the patients and wealth for the country.
The Unit therefore applies the guidelines of Standard UNE 166002:2014 “R&D&I Management Systems” and, as endorsement of its consistency with the said standard, holds the Certificate for its System issued by AENOR.
Among the System documents is the R&D&i Policy, a declaration of intent regarding the future management and approach of this Biogipuzkoa HRI strategic process and which, as a requirement of the Standard, must be made available to interested parties external to the Institute.
In the exceptional setting of San Sebastián, home of R&D&I in health, universities, research centres, technology centres and companies, the Unit serves as a connection between the people making up the Basque Country’s first Health Research Institute and all of the other organisations and companies referred to.
The Innovation Support Unit, through its participation in the Medical Technology Innovation Network (ITEMAS ISCIII), known from 2021 as Revitalisation and innovation of the industrial capacities of the NHS and their effective transfer to the production-sector, aims to boost translational research by generating innovation in the non-pharmacological sector of medical and health technologies and material, as regards equipment, devices, reagents, materials and ICT in healthcare. Nowadays the Biogipuzkoa HRI takes part in the ITEMAS ISCIII Management Board whose role is to support the network Coordinator on its key duties.
The Institute, through the Innovation Support Unit, has taken part in the Trans-border Network for Biomedical Research of the Pyrenees, REFBIO II, funded by POCTEFA (European Union Programme for Territorial Co-operation INTERREG V-A Spain-France-Andorra) aimed at promoting sustainable development of the border territory of the three countries.
Earlier, in REFBIO I, nine co-operative research projects were carried out with the participation of IIS Biogipuzkoa.
Our activities are mainly aimed at ensuring that the R+D results from the public-private collaboration reach society as a whole:
- Offering support from the moment a clinical need is detected by a health worker.
- Carrying out a search and assessment of already existing technological solutions.
- Search for partners and advice on the preparation of R+D projects.
- Search for funding.
- Advice to researchers on intellectual property.
- Advice to researchers on exploitation of results agreements.
- Negotiating with third parties for intellectual property licences and exploitation of results in projects in which the Institute participates.
- Ferritin-Mediated siRNA Delivery and Gene Silencing in Human Tumor and Primary cells.
- Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.
- Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells.
- SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression.
- Conjugated Polymers As Molecular Gates for Light-Controlled Release of Gold Nanoparticles.
- Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis (Epub ahead of print).
- Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
- Guide to Best Practices in Innovation Management.
- Guide to Implementation of the Innovation Management System according to standard UNE 166002:2014.
- Guide to Best Practices in Innovative Public Purchasing.
LIST OF PATENTS REQUESTED / OBTAINED
- Mutation detecting device.
- New compounds for regulating intracellular calcium homeostasis.
- Screening test for advanced colonic neoplasia by measuring faecal metabolites.
- Combined therapeutic strategy for polycystic liver diseases using new HDAC 61 inhibitors derived from UDCA.
- Identification of molecular patterns for the diagnosis and stratification of frail individuals.
- Mechanism for functional capacity evaluation.
- FOXO inhibitors: New Treatment for Amyotrophic Lateral Sclerosis (ALS).
- In vitro method and tools for the prognosis of Amyotrophic Lateral Sclerosis (ALS).
- SARS-COV-2 Detection Technology .
- New biomarkers for diagnosis and monitoring of Multiple Sclerosis.
- Hypoxia detection mechanism.
- Saliva-based test for Eosinophilic Esophagitis.
PRODUCTS ON THE MARKET
- Pneumococcal Serotyping Kit.
- Test to detect fatty liver blood markers in order to quantify the risk of disease (OWL Fat).
- Test to detect blood markers associated with DNA modifications which may cause Non-Alcoholic Fatty Liver Disease (OWL Genomics).
The Innovation Support Unit team is made up of the following members:
- Arantza Abad Alba Ph.D. : Innovation Support Unit Administrator: responsible for administration at the Innovation Support Unit.
- Olatz Arrizabalaga Garde Ph.D. : R&D&i Management and Scientific Coordination.
- Amaia Del Villar Álvarez PhD. : Innovation Support Unit External Agents Coordination.
- Marisabel Arzamendi Sesé: Project Unit Manager. R&D&i project administrative management. Competitive fund search.
- Julián de Frutos Soto: Evaluation-Quality Unit Manager. ISU (Innovation Support Unit) Advanced Technician for the R&D&I Management System certified by AENOR based on the UNE 166002 Standard.
- Catalina Arrieta Villalante: Technological Transfer Technician at Innovation Support Unit.
- Itxaso Calbano Osinaga: Methodologist-Statistician at Innovation Support Unit.
- Álvaro Ricón Rivera: Digital Innovation Technician at Innovation Support Unit.
- Maider San Torcuato Labaien: Innovation Management Technician at Innovation Support Unit.
- Sonsoles García García: Support Technician.
Julián de Frutos Soto
Tfno.: + 34 943 006129